Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Afatinib and Necitumumab in EGFR mutant NSCLC with Acquired Resistance to 1st or 3rd Generation EGFR Tyrosine Kinase Inhibitors Padda, S., Whisenant, J., Neal, J., York, S., Iams, W., Neuss, M., Reckamp, K., Preiss, J., Berry, L., Shyr, Y., Wakelee, H., Horn, L. ELSEVIER SCIENCE INC. 2021: S626
View details for Web of Science ID 000631349601560